Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on September 7, 2022. The registrant is an emerging growth company incorporated in Nevada, with principal executive offices in Boca Raton, Florida. The report primarily addresses upcoming corporate presentations by the Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate events and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document serves to notify investors of scheduled conference presentations.
Outlook, Management Commentary, and Risks
Upcoming Presentations: On September 7, 2022, the company announced that RJ Tesi, M.D., Chief Executive Officer, will present a corporate overview at the following events:
- H.C. Wainwright 24th Annual Global Investment Conference: September 12 - 14, 2022.
- Baird Global Healthcare Conference: September 13 - 14, 2022.
Risks and Contingencies: The filing does not disclose new risks, contingencies, or unusual items beyond the standard disclosure of upcoming investor communications.
Investor Verification Checklist
- Verify the date and time of the CEO's presentations at the H.C. Wainwright and Baird conferences.
- Review the press release (Exhibit 99.1) for any additional details on the corporate overview topics.
- Check subsequent filings (e.g., 10-Q or 10-K) for the actual financial metrics and operational updates discussed during these conferences.